Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials-Reference-Cited by-同舟云学术

Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials

Published:2014-04-30 Issue:11 Volume:30 Page:2295-2304
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Li Xuyuan¹,Wang Hongbiao¹,Lin Wenzhao¹,Xu Qini¹

Affiliation:

1. Department of Internal Medicine, Cancer Hospital of Shantou University Medical College Shantou, GuangdongChina

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/03007995.2014.909392

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC);Medicine;2016-12

2. Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer;BMC Medicine;2016-01-20

3. Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer;Cancer Chemotherapy and Pharmacology;2016-01-12

4. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2015-11

5. Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials;OncoTargets and Therapy;2015-08